



## Corporate Profile

### Corporate Profile

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes cancer immunotherapies against clinically-validated targets, such as PD-L1 and CTLA-4, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit [www.cytomx.com](http://www.cytomx.com) or follow us on Twitter.

## Stock Performance

### CTMX (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	C
Price	<b>\$33.73</b>
Change (%)	<b>▼ 0.27 (0.79%)</b>
Volume	154,913
52 Week Low	\$13.06
Market Cap	\$1,302,354,359
Rolling EPS	-1.84
PE Ratio	0
Shares Outstanding	38,611,158

Data as of 03/19/18 4:00 p.m. ET



## Recent Headlines

03/07/18

CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update

03/01/18

CytomX to Present at Upcoming Investor Conferences

02/22/18

CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	Description
03/14/18	10-K/A	Amendment to a previously filed 10-K
03/07/18	8-K	Report of unscheduled material events or corporate event
03/07/18	S-8	Securities offered to employees pursuant to employee benefit plans
03/07/18	10-K	Annual report which provides a comprehensive overview of the company for the past year

Data provided by Nasdaq. Minimum 15 minutes delayed.